Related Experiment Video
Updated: Jan 8, 2026
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
The LRRK2 P1446L mutation triggers dopaminergic neurodegeneration via DAPK1-mediated microglial neuroinflammation and
Liuyan Ding1, Hui Shu1, Minshan Chen1
1Department of Neurology, The First Affiliated Hospital of Guangzhou Medical university, Guangzhou, China.
Abstract:
Parkinson's disease (PD) involves dopaminergic neuron loss and neuroinflammation, with leucine-rich repeat kinase 2 (LRRK2) mutations identified as major genetic risk factors. However, the pathogenic mechanism of the novel LRRK2-P1446L mutation remains unknown. Here, we designed LRRK2-P1446L mutant mice and demonstrated that the novel LRRK2-P1446L mutation drives neurodegeneration through death-associated protein kinase 1 (DAPK1) dysregulation. This mutation downregulates LRRK2 while upregulating DAPK1, which concurrently triggers microglial PI3K/Akt-dependent NF-κB activation (inducing IL-1β/IL-6/TNF-α expression) and neuronal mitochondrial apoptosis (via a Bax/Bcl-2 imbalance). Integrative multiomics revealed suppressed expression of the neuroprotective molecule tuftsin, which negatively correlated with DAPK1 expression and was linked to microbiota alterations. Our work establishes DAPK1 as a pivotal hub mediating neuroinflammation and apoptosis in LRRK2-related PD pathogenesis, and reveals novel associations with the gut-brain axis. These findings support DAPK1 inhibition as a promising therapeutic strategy, while the negative correlation with tuftsin suggests its restoration may be a potential future avenue for intervention.
Insights
A novel LRRK2 mutation causes Parkinson's disease by upregulating DAPK1, leading to neuroinflammation and neuronal death. Restoring neuroprotective tuftsin may offer a therapeutic avenue.
Area of Science:
- Neuroscience
- Genetics
- Immunology
Background:
- Parkinson's disease (PD) is characterized by dopaminergic neuron loss and neuroinflammation.
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are significant genetic risk factors for PD.
- The pathogenic mechanism of the LRRK2-P1446L mutation was previously unknown.
Purpose of the Study:
- To elucidate the pathogenic mechanism of the novel LRRK2-P1446L mutation in Parkinson's disease.
- To investigate the role of DAPK1 dysregulation in LRRK2-related PD.
- To explore potential therapeutic strategies targeting DAPK1 and the gut-brain axis.
Main Methods:
- Generation of LRRK2-P1446L mutant mice.
- Analysis of microglial activation and inflammatory cytokine expression (IL-1β, IL-6, TNF-α).
- Assessment of neuronal apoptosis via mitochondrial pathways (Bax/Bcl-2 imbalance).
- Integrative multiomics to identify molecular alterations and correlations.
Main Results:
- The LRRK2-P1446L mutation downregulates LRRK2 and upregulates DAPK1, driving neurodegeneration.
- Upregulated DAPK1 activates microglial NF-κB signaling and induces neuronal apoptosis.
- Suppressed expression of the neuroprotective molecule tuftsin was observed, correlating negatively with DAPK1.
- Alterations in gut microbiota were linked to DAPK1 dysregulation.
Conclusions:
- DAPK1 is a key mediator of neuroinflammation and apoptosis in LRRK2-related PD pathogenesis.
- The findings highlight novel associations between LRRK2-PD, the gut-brain axis, and DAPK1.
- DAPK1 inhibition presents a promising therapeutic strategy, and tuftsin restoration is a potential future intervention.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:22Lysosomal Hydrolases